Association of Anti-Modified Citrullinated Vimentin with Subclinical Atherosclerosis in Early Rheumatoid Arthritis Compared with Anti-Cyclic Citrullinated Peptide

To investigate anti-modified citrullinated vimentin (anti-MCV) in early rheumatoid arthritis (RA), including correlation with disease activity and cardiovascular risk factors, compared with anti-cyclic citrullinated peptides (anti-CCP3). Anti-MCV and anti-CCP3 concentrations were measured in 100 pat...

Full description

Saved in:
Bibliographic Details
Published in:Journal of rheumatology 2011-05, Vol.38 (5), p.828-834
Main Authors: EL-BARBARY, Amal M, KASSEM, Elham M, EL-SERGANY, Mervat A. S, ESSA, Salwa A-M, ELTOMEY, Mohamed A
Format: Article
Language:English
Subjects:
Adult
Aged
Antibodies, Anti-Idiotypic - blood
Apolipoprotein A-I - blood
Apolipoproteins B - blood
Arthritis, Rheumatoid - immunology
Atherosclerosis (general aspects, experimental research)
Atherosclerosis - immunology
Autoantibodies - blood
Biological and medical sciences
Blood and lymphatic vessels
Cardiology. Vascular system
Carotid Artery, Common - diagnostic imaging
Citrulline - immunology
Diseases of the osteoarticular system
Enzyme-Linked Immunosorbent Assay
Female
Humans
Inflammatory joint diseases
Male
Medical sciences
Middle Aged
Nephelometry and Turbidimetry
Peptides, Cyclic - immunology
Risk Factors
Sensitivity and Specificity
Severity of Illness Index
Ultrasonography
Vimentin - immunology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To investigate anti-modified citrullinated vimentin (anti-MCV) in early rheumatoid arthritis (RA), including correlation with disease activity and cardiovascular risk factors, compared with anti-cyclic citrullinated peptides (anti-CCP3). Anti-MCV and anti-CCP3 concentrations were measured in 100 patients with early RA and 100 healthy controls at baseline to determine sensitivity and specificity. Patients received methotrexate (MTX) 0.2 mg/kg/week plus prednisone 10 mg/day. Anti-MCV, anti-CCP3, rheumatoid factor (RF), Disease Activity Score for 28 joints (DAS-28), lipid profile, erythrocyte sedimentation rate (ESR), high-sensitivity C-reactive protein assay (hsCRP), homeostasis model assessment for insulin resistance (HOMA-IR) index, tumor necrosis factor-α (TNF-α), interleukin 6 (IL-6), and carotid intima-media thickness (cIMT) were measured before and after 12 months of treatment. The sensitivity and specificity for anti-MCV antibody were 75% and 90%, respectively, and for anti-CCP3 antibody 71% and 96%. Serum anti-MCV and serum anti-CCP3 levels at baseline were positively correlated with hsCRP, IL-6, HOMA-IR index, serum RF levels (p < 0.001), and cIMT (p < 0.05). Serum anti-MCV was positively correlated with serum anti-CCP3 levels. There were significant positive correlations between the percentage of changes of anti-MCV levels versus changes in DAS-28, ESR, hsCRP, atherogenic ratios (TC/HDL-C and LDL-C/HDL-C), apolipoprotein A-I, IL-6, TNF-α, HOMA-IR index, and cIMT. These correlations were not found between changes in anti-CCP3 levels compared to clinical, laboratory, and radiological variables. Anti-MCV was as sensitive as anti-CCP3 in diagnosing early RA. Anti-MCV testing appears to be useful for monitoring associated subclinical atherosclerosis in early RA.
ISSN:0315-162X
1499-2752
DOI:10.3899/jrheum.101143